The Drug That Nobody Talks About Enough: Regeneron's Hidden Compounding Machine

Analysis done February 26, 2026 | Quality Compounder | Part 3 of 3 Part 1: Gilead Sciences (GILD): The Fortress Nobody's Paying Attention To | GNG Research Part 2: Part 2 of 3: The Night the Organ Monopoly Proved It Was Real | GNG Research Rating: BUY (Staged, Pullback Discipline) | 12-Month Target: $900 | Close: $789.54 Wall Street has spent 18 months arguing about what Regeneron is losing . The EYLEA cliff. Biosimilar creep. The eye franchise that built the company slowly giving ground to cheaper competitors. It's a legitimate worry, and it has kept the stock range-bound while the S&P rallied around it. But here's the thing about tunnel vision: when everyone's watching the same exit, they miss what's walking in the front door. This week, Regeneron's (REGN) "other" business, the one the market has largely treated as a footnote, just quietly got more valuable. On February 24, the FDA expanded Dupixent's label again, this time for allergic fungal rhinosinusitis (AFRS), adding yet another addressable patient population to a drug that already treats eczema, asthma, nasal polyps, eosinophilic esophagitis, and COPD. Four days earlier, the FDA accepted the company's BLA for garetosmab with Priority Review status, validating a rare disease program that most models assign zero credit for. The question for investors isn't whether Regeneron is a good company. It obviously is: 98th percentile quality score, 120x interest coverage, Altman Z-Score of 7.8, and a debt-to-equity ratio so low (0.1) it barely registers. The question is whether it's a good buy at these prices . The honest answer: not quite yet. But get the entry right, and you're holding one of the most durable franchises in biopharma at a price that doesn't require perfection. The Business They Built and the Transition They're Managing